Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma

Jinno,Teppei; Kawano,Shintaro; Maruse,Yasuyuki; Matsubara,Ryota; Goto,Yuichi; Sakamoto,Taiki; Hashiguchi,Yuma; Kaneko,Naoki; Tanaka,Hideaki; Kitamura,Ryoji; Toyoshima,Takeshi; Jinno,Akiko; Moriyama,Masafumi; Oobu,Kazunari; Kiyoshima,Tamotsu; Nakamura,Seiji

doi:10.3892/or.2015.3838

Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma

Authors:
- Teppei Jinno
- Shintaro Kawano
- Yasuyuki Maruse
- Ryota Matsubara
- Yuichi Goto
- Taiki Sakamoto
- Yuma Hashiguchi
- Naoki Kaneko
- Hideaki Tanaka
- Ryoji Kitamura
- Takeshi Toyoshima
- Akiko Jinno
- Masafumi Moriyama
- Kazunari Oobu
- Tamotsu Kiyoshima
- Seiji Nakamura
View Affiliations

Affiliations: Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan, Laboratory of Oral Pathology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Published online on: March 6, 2015 https://doi.org/10.3892/or.2015.3838
Pages: 2161-2168
Copyright: © Jinno et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have revealed that cancer cells are exacerbated by chronic inflammation. The present study examined the immunohistochemical expression for interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, in oral squamous cell carcinoma (OSCC) to elucidate the association of IL-6 expression with tumor progression, chemoresistance and prognosis. Seventy-eight patients with primary OSCC were analyzed by immunohistochemical staining for IL-6. These labeling indexes (LIs) were calculated and evaluated in association with the clinicopathologic characteristics and prognosis in the OSCC patients. The patients were divided into three groups as follows: negative group = LI <5%; low IL-6 group = 5% ≤ LI <30%; high IL-6 group = LI ≥30%. The patient numbers of the negative, low and high expression groups were 24, 22 and 32, respectively. In the high IL-6 expression group, IL-6 receptor (IL-6R), phospho‑signal tranducer and activator of transcription 3 (p-STAT3) were also detected in almost all the cancer cells. The prevalence of the cervical lymph node or the distant metastasis in the high expression group was significantly higher than those in the negative and low expression groups. Furthermore, the high expression group had a significantly poorer tumor response to the preoperative chemoradiotherapy and a more unfavourable prognosis than the negative and the low expression groups. Interestingly, IL-6, IL-6R and p-STAT3 were expressed in the residual cancer cells of all the patients in the high expression group with poor response to chemoradiotherapy. These results suggested that IL-6 signaling possibly is involved in the progression and treatment‑resistance of OSCC and IL-6 expression in cancer cells could be a useful predictive factor of poor response to chemoradiotherapy and unfavorable prognosis.

View Figures

View References

1	Funk GF, Karnell LH, Robinson RA, et al: Presentation, treatment, and outcome of oral cavity cancer: A National Cancer Data Base report. Head Neck. 24:165–180. 2002. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kirita T, Ohgi K, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, Mishima K and Sugimura M: Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: An analysis of long-term results. Oral Oncol. 35:597–606. 1999. View Article : Google Scholar
4	Freier K, Engel M, Lindel K, Flechtenmacher C, Mühling J, Hassfeld S and Hofele C: Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): A retrospective analysis of 207 patients. Oral Oncol. 44:116–123. 2008. View Article : Google Scholar
5	Mohr C, Bohndorf W, Carstens J, et al: Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. Int J Oral Maxillofac Surg. 23:140–148. 1994.PubMed/NCBI
6	Klug C, Berzaczy D, Voracek M and Millesi W: Preoperative chemoradiotherapy in the management of oral cancer: A review. J Craniomaxillofac Surg. 36:75–88. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, Yagyuu T and Hasegawa M: Preoperative concurrent chemoradiotherapy for stages II–IV oral squamous cell carcinoma: A retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg. 41:421–428. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kawano S, Zheng Y, Oobu K, Matsubara R, Goto Y, Chikui T, Yoshitake T, Kiyoshima K, Jinno T, Maruse Y, Mitate E, Kitmura R, Tanaka H, Toyoshima T, Sugiura T and Nakamura S: Clinicopathological evaluation of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma. Oncol Lett (In press);
9	Matsubara R, Kawano S, Kiyosue T, Goto Y, Hirano M, Jinno T, Toyoshima T, Kitamura R, Oobu K and Nakamura S: Increased ΔNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. Int J Oncol. 39:1391–1399. 2011.PubMed/NCBI
10	Kiyosue T, Kawano S, Matsubara R, Goto Y, Hirano M, Jinno T, Toyoshima T, Kitamura R, Oobu K and Nakamura S: Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma. Int J Clin Oncol. 18:154–163. 2013. View Article : Google Scholar
11	Goto Y, Kawano S, Matsubara R, et al: Possible involvement of ΔNp63 downregulation in the invasion and metastasis of oral squamous cell carcinoma via induction of a mesenchymal phenotype. Clin Exp Metastasis. 31:293–306. 2014. View Article : Google Scholar
12	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kishimoto T: Interleukin-6: From basic science to medicine - 40 years in immunology. Annu Rev Immunol. 23:1–21. 2005. View Article : Google Scholar
14	Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J and Talpaz M: Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res. 53:2118–2122. 1993.PubMed/NCBI
15	Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 117:3660–3663. 2007. View Article : Google Scholar : PubMed/NCBI
16	Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM and Kuo ML: IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer. 120:2600–2608. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ and Chan HL: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 124:2766–2770. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD and Chen MF: Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 76:1214–1224. 2010. View Article : Google Scholar : PubMed/NCBI
19	Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S, Ma D, Chen G and Gao Q: Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 435:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang YH, Wang YN, Li J and Gao FG: Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation. Cancer Sci. 105:1220–1227. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH, Witte Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss; New York, NY: 2002
22	Wahi PN, Cohen B, Luthra UK, et al: Histological consideration. Histological Typing of Oral and Orpharyngeal Tumors. Wahi PN, Cohen B, Luthra UK, et al: World Health Organization; Geneva: pp. 15–19. 1977
23	Yamamoto E, Miyakawa A and Kohama G: Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg. 6:938–947. 1984. View Article : Google Scholar : PubMed/NCBI
24	Shimosato Y, Oboshi S and Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol. 1:19–35. 1971.
25	Riedel F, Zaiss I, Herzog D, Götte K, Naim R and Hörmann K: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 25:2761–2765. 2005.PubMed/NCBI
26	Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT and Teknos TN: Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 113:750–757. 2008. View Article : Google Scholar : PubMed/NCBI
27	Meyer F, Samson E, Douville P, Duchesne T, Liu G and Bairati I: Serum prognostic markers in head and neck cancer. Clin Cancer Res. 16:1008–1015. 2010. View Article : Google Scholar : PubMed/NCBI
28	Mojtahedi Z, Khademi B, Hashemi SB, Abtahi SM, Ghasemi MA, Fattahi MJ and Ghaderi A: Serum interleukin-6 concentration, but not interleukin-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res. 17:7–10. 2011. View Article : Google Scholar
29	Sato J, Ohuchi M, Abe K, Satoh T, Abe T, Yamazaki Y, Satoh A, Notani K and Kitagawa Y: Correlation between salivary interleukin-6 levels and early locoregional recurrence in patients with oral squamous cell carcinoma: preliminary study. Head Neck. 35:889–894. 2013. View Article : Google Scholar
30	Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, Oike Y, Ibusuki M, Hiraki A, Nakayama H, Shinohara M and Ando Y: Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol. 225:142–150. 2011. View Article : Google Scholar : PubMed/NCBI
31	Lane D, Matte I, Rancourt C and Piché A: Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 11:2102011. View Article : Google Scholar : PubMed/NCBI
32	Chen MF, Chen PT, Lu MS, Lin PY, Chen WC and Lee KD: IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 12:262013. View Article : Google Scholar : PubMed/NCBI
33	Hirano T, Nakajima K and Hibi M: Signaling mechanisms through gp130: A model of the cytokine system. Cytokine Growth Factor Rev. 8:241–252. 1997. View Article : Google Scholar
34	Chakravarti N, Myers JN and Aggarwal BB: Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer. 119:1268–1275. 2006. View Article : Google Scholar : PubMed/NCBI
35	Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol. 197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
36	Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
37	Hsu CP and Chung YC: Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res. 26:4607–4614. 2006.
38	Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 46:1223–1231. 2010. View Article : Google Scholar : PubMed/NCBI
39	Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T and Nakanishi O: The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis. 17:462–468. 2011. View Article : Google Scholar : PubMed/NCBI
40	Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki Y: Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 18:5144–5153. 2012. View Article : Google Scholar : PubMed/NCBI
41	Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ and Li LZ: Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 295:110–123. 2010. View Article : Google Scholar : PubMed/NCBI
42	Gilbert LA and Hemann MT: DNA damage-mediated induction of a chemoresistant niche. Cell. 143:355–366. 2010. View Article : Google Scholar : PubMed/NCBI
43	Chen CJ, Sung WW, Lin YM, Chen MK, Lee CH, Lee H, Yeh KT and Ko JL: Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. PLoS One. 7:e501042012. View Article : Google Scholar : PubMed/NCBI
44	Wang YF, Chang SY, Tai SK, Li WY and Wang LS: Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck. 24:850–858. 2002. View Article : Google Scholar : PubMed/NCBI